Jasper Therapeutics (JSPRW) Stock Price, News & Analysis

Company Overview

Jasper Therapeutics is a clinical-stage biotechnology company developing antibody therapies that target c-Kit, also known as CD117. Its lead candidate, briquilimab (formerly JSP191), is a monoclonal antibody designed to bind this protein on mast cells and hematopoietic stem cells.

The company is evaluating briquilimab for mast cell–driven conditions, including chronic spontaneous urticaria and chronic inducible urticaria. Earlier development programs explored its potential use in conditioning patients for stem cell transplants and gene therapies, including for blood and immune system disorders.

Jasper is based in Redwood City, California. Its work is focused on clinical development, and its programs remain investigational.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.15
• Volume: N/A
• Average Volume: 32,893 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:JSPRW
• CIK: 1788028
• Web: jaspertherapeutics.com
• Phone: 650-549-1400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A